Table 1.
Baseline patient characteristics
| Characteristic | All | CD56−CD16+ NK cells ≤10% | CD56−CD16+ NK cells >10% | P |
| Patients, No. (%) | 48 (100) | 35 (72.9) | 13 (27.1) | |
| Age at diagnosis, years, mean (SD) | 54.0 (14.0) | 54.4 (14.2) | 53.2 (14.0) | 0.871 |
| Patient sex | ||||
| Female | 28 (58.3) | 18 (51.4) | 10 (76.9) | 0.188 |
| Male | 20 (41.7) | 17 (48.6) | 3 (23.1) | |
| Median white blood cells, 109 cells/L (SD) | 11.0 (40.5) | 12.4 (43.5) | 6.0 (31.1) | 0.476 |
| Cytogenetic prognosis, No. (%) | ||||
| Favorable | 10 (20.8) | 7 (20.0) | 3 (23.1) | 0.342 |
| Intermediate | 26 (54.2) | 21 (60.0) | 5 (38.5) | |
| Adverse | 12 (25.0) | 7 (20.0) | 5 (38.5) | |
| Mutations in intermediate cytogenetic group, No. (%) | ||||
| Analyzed | 24/26 | 19/21 | 5/5 | NA |
| FLT3 ITDmut | 6 (25.0) | 3 (15.8) | 3 (60.0) | |
| NPM1mut | 13 (54.2) | 9 (47.4) | 4 (80.0) | |
| CEBPαmut/FLT3wt NPM1wt | 3 (12.5) | 3 (15.8) | 0 (0.0) | |
| ELN, No. (%) | ||||
| Favorable | 19 (39.6) | 15 (42.9) | 4 (30.8) | 0.417 |
| Intermediate | 17 (35.4) | 13 (37.1) | 4 (30.8) | |
| Adverse | 12 (25.0) | 7 (20.0) | 5 (38.5) | |
| Postinduction CR, No. (%) | 39 (81.3) | 30 (85.7) | 9 (69.2) | 0.228 |
| No postinduction CR | 9 (18.8) | 5 (14.3) | 4 (30.8) | |
| Induction death | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| No CR achieved | 9 (18.8) | 5 (14.3) | 4 (30.8) | |
| Relapse, No. (%) | 19 (39.6) | 12 (34.3) | 7 (53.8) | 0.065 |
| No relapse | 20 (41.7) | 18 (51.4) | 2 (15.4) | |
| Consolidation, No. (%) | ||||
| Chemotherapy + Allo-SCT | 16 (33.3) | 13 (37.1) | 3 (23.1) | NA |
| in CR1 | 8 (16.7) | 7 (20.0) | 1 (7.7) | |
| in CR > 1 | 8 (16.7) | 6 (17.1) | 2 (15.4) | |
| Blasts (blood) at diagnosis, mean (SD) | 50.7 (32.9) | 52.6 (34.3) | 45.1 (29.0) | 0.540 |
| Blasts (BM) at diagnosis, mean (SD) | 60.6 (25.8) | 64.1 (27.3) | 51.2 (19.3) | 0.104 |
BM, bone marrow; CR, complete remission; ELN, European Leukemia Net genetic classification 2010 (doi: 10.1182/blood-2009-07-235358); ITD, internal tandem duplication; and NA, not available.